Kena A. Swanson

Kena A. Swanson publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Kena A. Swanson sits on this spectrum.

Kena A. Swanson D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Kena A. Swanson sits on this spectrum.

Best Publications

• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

  Fernando P. Polack;Stephen J. Thomas;Nicholas Kitchin;Judith Absalon

  14076
  Citations

• Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

  Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin

  2629
  Citations

• COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.

  Ugur Sahin;Alexander Muik;Evelyna Derhovanessian;Isabel Vogler

  2204
  Citations

• Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

  Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon

  1672
  Citations

• Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.

  Unknown

  992
  Citations

• Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

  Robert W Frenck;Nicola P Klein;Nicholas Kitchin;Alejandra Gurtman

  847
  Citations

• BNT162b vaccines protect rhesus macaques from SARS-CoV-2.

  Annette B. Vogel;Isis Kanevsky;Ye Che;Kena A. Swanson

  686
  Citations

• Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera

  Unknown

  678
  Citations

• Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.

  Unknown

  676
  Citations

• Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

  Emmanuel B. Walter;Kawsar R. Talaat;Charu Sabharwal;Alejandra Gurtman

  599
  Citations

• Neutralizing Activity of BNT162b2-Elicited Serum.

  Yang Liu;Jianying Liu;Hongjie Xia;Xianwen Zhang

  582
  Citations

• Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.

  Xuping Xie;Yang Liu;Jianying Liu;Xianwen Zhang

  580
  Citations

• Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.

  Alexander Muik;Ann-Kathrin Wallisch;Bianca Sänger;Kena A. Swanson

  527
  Citations

• SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.

  Ann R Falsey;Robert W Frenck;Edward E Walsh;Nicholas Kitchin

  373
  Citations

• BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.

  Jianying Liu;Yang Liu;Hongjie Xia;Jing Zou

  342
  Citations

• Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine

  Unknown

  244
  Citations

• Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2

  Unknown

  182
  Citations

• Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study.

  Unknown

  178
  Citations

• Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years

  Unknown

  175
  Citations

• RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study

  Edward E. Walsh;Robert Frenck;Ann R. Falsey;Nicholas Kitchin

  170
  Citations